With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
This article was originally published in The Pink Sheet Daily
Executive Summary
Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.
You may also be interested in...
Price Discount Paves The Way For NICE To Clear GSK’s Revolade
U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.
NICE Gives Thumbs Down to Simponi--For Now
The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.
NICE Rejects Revolade For Bleeding Disorders; GSK Considering Its Options
UK's cost effectiveness watchdog is uncertain about Revolade's long-term effects and cost